PresentationMichael KingRodman & Renshaw Research Okay. All right. So then we can begin. Sorry about all the confusion everybody. We're going to kick it off right away in the interest of time. So we're pleased to be joined by the management from Biomea, including a welcome late addition Mick Hitchcock, Interim CEO; Ramses Erdtmann, Founder, Chief Operating Officer and President; and finally, Steve Morris, who is the Chief Development Officer. So I'm just going to make a couple of opening remarks, and we'll ...

Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease Rezurock is now approved in the EU for adults and children aged 12 years and older with chronic GVHD, providing a new medicine for patients with limited treatment options Paris, March 31, 2026. The European Commission has granted a conditional marketing authorisation for Rezurock (belumosudil) for the treatment of chronic graft-versus-host disease (GVHD) in adults and in children aged 12 years and older with a body weight of at lea ...

New York, New York--(Newsfile Corp. - March 30, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If you purchased Aquestive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency ...

Ten stocks stood firmer on Monday, clocking gains and bucking a mostly pessimistic broader market, as investors gobbled up shares ahead of dividend payments, while digesting analyst ratings and other macroeconomic factors, among others.Meanwhile, Wall Street’s three major indices finished mixed, with the Dow Jones the only gainer, up 0.11 percent. The S&P 500 and the Nasdaq both fell by 0.39 percent and 0.73 percent, respectively.In this article, we spotlight the 10 top-performing companies on Monday and de ...

PITTSBURGH, March 30, 2026 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (“Lipella” or the “Company”), a clinical-stage biotechnology company, announced today that it filed a voluntary petition for relief under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the Western District of Pennsylvania (the “Court”). The Company intends to undergo a 363 sale process under Chapter 11 in order to maximize value for creditors. In connection with the Chapter 11 cases, the Company exp ...

NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October 10, 2023 and December 26, 2025, inclusive (the “Class Period”), of the important April 7, 2026 lead plaintiff deadline. SO WHAT: If you purchased Inovio securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. W ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Aquestive (AQST) To Contact Him Directly To Discuss Their Options If you purchased or acquired Aquestive securities between June 16, 2025 to January 8, 2026 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648. Click here to participate in the action. NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- What’s Happening: ...

Company advances manufacturing, toxicology, patent and regulatory milestones while building a broader pharmaceutical development platform Jericho, New York, March 30, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a pharmaceutical development company focused on advancing therapeutic assets for serious diseases with significant unmet medical need, today provided a business update in conjunction with the filing of its Annual Report on Form 10-K for the year ...

<!doctype html> <!-- For structured data --> <!-- For language declaration --> RARE Deadline: RARE Investors with Losses in Excess of $100K Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit <!-- Additional Authorable Meta tags --> Accessibility StatementSkip NavigationNEW YORK, March 30, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and Dece ...

Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results Back to the Newsroom Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results TAAPTM (Opioid Abuse Deterrent) Program Update Ensysce's lead drug candidate, PF614, is a Trypsin-Activated Abuse Protection (TAAPTM) extended-release oxycodone designed to deliver effective pain relief while incorporating built-in abuse protection. Through proprietary chemical modification of ox ...